2. Cytotoxicity of natural killer cells against A549 lung cancer cells in vitro
Main Article Content
Abstract
The purpose of this investigation was to evaluate the cytotoxic activity of natural killer (NK) cells isolated from lung cancer patients against the lung cancer (A549) cell line. Two samples of NK1 and NK2 cells (E) were activated, proliferated in vitro, and co-cultured with A549 cells (T) with E:T ratios of 1:1, 2:1, 5:1, 10:1, and 20:1 for 24 and 48 hours, respectively. Results of co-culturing for 24 hours indicated that at the ratios of E: T cells of 1:1, 2:1, and 5:1, respectively, the cytotoxicity of NK cells was still limited, with the survival rate of A549 cells exceeding 90%. However, at a ratio of 10:1 and 20:1, the cytotoxicity of NK cells was obviously demonstrated, with an A549 cell survival rate of 11.54%. With an E:T ratio of 20:1, the A549 cell survival rate dropped to as low as 0.53% after 48 hours of co-cultivation. Consequently, when co-culturing A549 lung cancer cells with natural killer cells, the survival rate of A549 lung cancer cells was significantly affected over time, as was the rate of co- culture.
Article Details
Keywords
Natural killer cells, lung cancer, A549 cells
References
2. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020; 19(3): 200-218. doi:10.1038/s41573-019-0052-1.
3. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013): 44-49. doi:10.1126/science.1198687.
4. Dianat-Moghadam H, Rokni M, Marofi F, Panahi Y, Yousefi M. Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells. J Cell Physiol. 2018; 234(1): 259-273. doi:10.1002/jcp.26878.
5. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006; 20(3): 123-137. doi:10.1016/j.blre.2005.10.001.
6. Cancer Immunotherapy Principles and Practice, Second Edition. Accessed July 19, 2023. https://www.springerpub.com/cancer-immunotherapy-principles-and-practice-second- edition-9780826137425.html.
7. Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology. 2009; 128(2): 151-163. doi:10.1111/j.1365-2567.2009.03167.x.
8. Tartour E, Zitvogel L. Lung cancer: potential targets for immunotherapy. Lancet Respir Med. 2013; 1(7): 551-563. doi:10.1016/S2213-2600(13)70159-0.
9. Fu J, Mao J, Wang C. The microRNA-152/human leukocyte antigen-G axis affects proliferation and immune escape of non-small cell lung cancer cells. J Int Med Res. 2020; 48(11): 0300060520970758. doi:10.1177/0300060520970758.
10. Yang L, Shen M, Xu LJ, et al. Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition. Sci Rep. 2017; 7(1): 7958. doi:10.1038/s41598-017-08483-z.
11. Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015; 33(1): 74-82. doi:10.1200/JCO.2014.57.3329.
12. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001; 166(1): 678-689. doi:10.4049/jimmunol.166.1.678.
13. Barsoum IB, Hamilton TK, Li X, et al. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res. 2011; 71(24): 7433-7441. doi:10.1158/0008-5472.CAN-11-2104.
14. Baginska J, Viry E, Paggetti J, et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol. 2013; 4:490. doi:10.3389/fimmu.2013.00490.
15. Mamessier E, Sylvain A, Thibult ML, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011; 121(9): 3609- 3622. doi:10.1172/JCI45816.